Evidence map›Paper›PMID 28119528›Full record

ArticleLeukemia2017

Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.

C Ustun, F Giannotti, M-J Zhang, H-L Wang, C Brunstein, M Labopin, V Rocha, M de Lima, F Baron, B M Sandmaier and 5 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Review
  3. Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITDTransplantation and cellular therapy · 2024
    Observational
  4. Article
  5. In 2022, which is preferred: haploidentical or cord transplant?Hematology. American Society of Hematology. Education Program · 2022
    Article
  6. Article
  7. Cost-effectiveness of gilteritinib for relapsed/refractoryJournal of managed care & specialty pharmacy · 2021
    Article
  8. Observational
  9. Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Article
  10. Optimizing cord blood selection.Hematology. American Society of Hematology. Education Program · 2019
    Review
  11. Review
  12. Article
  13. UCB HCT in FLT3+ AML.Oncotarget · 2017
    Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 7 countries.

C UstunDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN, USA.
F GiannottiService d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
M-J ZhangCIBMTR (Center for International Blood and Marrow Transplantation), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
H-L WangCIBMTR (Center for International Blood and Marrow Transplantation), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
C BrunsteinUniversity of Minnesota Medical Center Fairview, Minneapolis, MN, USA.
M LabopinEuropean Group for Blood and Marrow Transplantation, Leiden, The Netherlands.
V RochaChurchill Hospital, Oxford, UK.
M de LimaDepartment of Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.
F BaronCentre Hospitalier Universitaire de LiFge, Domaine Universityaire du Sart Tilman, Leige, Belgium.
B M SandmaierDivision of Medical Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
M EapenCIBMTR (Center for International Blood and Marrow Transplantation), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
E GluckmanEurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France.
A NaglerThe Bone Marrow Transplantation Department, Division of Internal Medicine, The Chaim Sheba Medical Center, Ramat-Gan, Israel.
D J WeisdorfDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN, USA.
A RuggeriService d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
Medical College of Wisconsin · USUniversité Paris Cité · FRUniversity of Minnesota Medical Center · USCentre Hospitalier Universitaire de Liège · BEChurchill Hospital · GBSheba Medical Center · ILSorbonne Université · FRUniversity Hospitals Cleveland Medical Center · USUniversity of Washington · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
NCI NIH HHS P30 CA077598NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294
6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FMS-like tyrosine kinase 3+ (FLT3+) acute myeloid leukemia (AML), which has poor prognosis because of high relapse rates. Umbilical cord blood (UCB) HCT outcomes are largely unknown in this population. We found that compared with sibling HCT, relapse risks were similar after UCB (n=126) (hazard ratio (HR) 0.86, P=0.54) and URD (n=91) (HR 0.81, P=0.43). UCB HCT was associated with statistically higher non-relapse mortality compared with sibling HCT (HR 2.32, P=0.02), but not vs URD (HR 1.72, P=0.07). All three cohorts had statistically nonsignificant 3-year LFS: 39% (95% confidence interval (CI): 30-47) after UCB, 43% (95% CI: 30-54) after sibling and 50% (95% CI: 40-60) after URD. Chronic graft-versus-host disease rates were significantly lower after UCB compared with either sibling (HR 0.59, P=0.03) or URD (HR 0.49, P=0.001). Adverse factors for LFS included high leukocyte count at diagnosis and HCT during CR2 (second CR). UCB is a suitable option for adults with FLT3+ AML in the absence of an human leukocyte antigen-matched sibling and its immediate availability may be particularly important for FLT3+ AML where early relapse is common, thus allowing HCT in CR1 (first CR) when outcomes are best.

Indexed as

Cord Blood Stem Cell TransplantationAdolescentAdultAgedFemaleFollow-Up StudiesGraft vs Host DiseaseHumansLeukemia, Myeloid, AcuteMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRemission InductionRetrospective Studies

Identifiers

PMID28119528
PMCPMC5462854
OpenAlexW2582077645

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.